As we all know, earnings announcement is today. Since I first covered this company in august, many positive things have occurred within Amylin Pharmaceuticals Inc. (AMLN). It has been upgraded by three firms and coverage was initiated by a fourth, we've seen a new addition to the board of directors, and most importantly, people have been buying the stock. Here is what one analyst wrote about their new drug Byetta that treats type 2 diabetes, "We continue to believe that Byetta will exceed Street expectations and upside to estimates could result in a second leg of stock appreciation near term." I will be surprised if they release anything other than good news after the bell today.
**update** AMLN hit the low end of the estimate and the stock is heading south in after hours trading... say no to drugs